Jun 2025Revenue $65.1M/yrExpenses $229M/yr
No trendCash runway ≈ 2 months from Jun 2025
Figures by year
When will Adaptimmune Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2025, revenue was $65.1M and expenses $229M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $178M | $247M | −$68.8M |
| Dec 2023 | $60.3M | $200M | −$140M |
| Dec 2022 | $27.1M | $191M | −$164M |
| Dec 2021 | $6.15M | $168M | −$162M |
| Dec 2020 | $3.96M | $137M | −$133M |
| Dec 2019 | $1.12M | $141M | −$140M |
| Dec 2018 | $59.5M | $142M | −$82.4M |
| Dec 2017 | $37.8M | $118M | −$80.7M |
| Dec 2016 | $14.2M | $87.0M | −$72.8M |
| Jun 2015 | $9.87M | $34.5M | −$24.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.